Shinichiro Okauchi1, Takeshi Numata2, Takeshi Nawa3, Hideo Ichimura3, Takefumi Saito4, Kenji Hayashihara4, Hideyasu Yamada5, Hiroaki Satoh6, Takeshi Endo2, Yoshihisa Inage2, Takayuki Kaburagi7, Moriyuki Kiyoshima7, Yutaka Yamada7, Tomohiro Tamura7, Kazuhito Saito8, Masaharu Inagaki8, Nobuyuki Hizawa9, Yukio Sato9, Toshihiro Shiozawa9, Ikuo Sekine9, Hiroichi Ishikawa10, Koichi Kurihima10, Mitsuaki Sakai10, Koichi Kamiyama11, Masaki Kimura11, Norihiro Kikuchi12, Hiroyuki Nakamura13, Kinya Furukawa13, Takahide Kodama14, Kunihiko Miyazaki14, Takaaki Yamashita15, Shigen Hayashi16, Yasunori Funayama17, Akihiro Nomura16. 1. Division of Respiratory Medicine, Mito Kyodo General Hospital-Mito Medical Center, University of Tsukuba, Mito, Japan. 2. Divisions of Respiratory Medicine and Thoracic Surgery, Mito Medical Center, Mito, Japan. 3. Divisions of Respiratory Medicine and Thoracic Surgery, Hitachi General Hospital, Hitachi, Japan. 4. Division of Respiratory Medicine, Ibarakihigashi Hospital, Tokai, Japan. 5. Division of Respiratory Medicine, Hitachinaka Medical Center, University of Tsukuba, Mito, Japan. 6. Division of Respiratory Medicine, Mito Kyodo General Hospital-Mito Medical Center, University of Tsukuba, Mito, Japan hirosato@md.tsukuba.ac.jp. 7. Respiratory Center, Ibaraki Prefectural Central Hospital, Kasama, Japan. 8. Divisions of Respiratory Medicine and Thoracic Surgery, Tsuchiura Kyodo General Hospital, Tsuchiura, Japan. 9. Faculty of Clinical Medicine, University of Tsukuba, Tsukuba, Japan. 10. Divisions of Respiratory Medicine and Thoracic Surgery, Tsukuba Medical Center Hospital, Tsukuba, Japan. 11. Division of Thoracic Surgery, Tsukuba Kinen Hospital, Tsukuba, Japan. 12. Division of Respiratory Medicine, Kasumigaura Medical Center, Tsuchiura, Japan. 13. Divisions of Respiratory Medicine and Thoracic Surgery, Tokyo Medical University, Ibaraki Medical Center, Ami-machi, Japan. 14. Division of Respiratory Medicine, Ryugasaki Saiseikai Hospital, Ryugasaki, Japan. 15. Division of Respiratory Medicine, JA Toride Medical Center, Toride, Japan. 16. Division of Respiratory Medicine, Seinan Medical Center, Sakai-machi, Japan. 17. Division of Respiratory Medicine, Tsukuba Gakuen General Hospital, Tsukuba, Japan.
Abstract
BACKGROUND/AIM: To describe real clinical outcomes when using systemic therapy to treat non-small cell lung cancer (NSCLC) patients who have anaplastic lymphoma kinase (ALK) fusion gene mutation. PATIENTS AND METHODS: We performed a retrospective chart review from April 2008 to March 2019 sourced from 16 medical institutes that cover a population of three million people. RESULTS: There were 129 ALK rearranged NSCLC patients. Among them, 103 patients including 40 recurrent disease cases received ALK-tyrosine kinase inhibitors (TKI) and chemotherapy. Our treatment results were comparable to previously reported clinical trials and clinical practice studies. First-line alectinib, treatment sequence of ALK-TKI followed by another ALK-TKI, and pemetrexed-containing chemotherapy contributed to the outcome of treatment. CONCLUSION: By arrangement of treatment such as treatment sequence of ALK-TKI and chemotherapy regimen, it might be possible to obtain a treatment outcome almost equivalent to those of clinical trials even in real clinical practice. Copyright
BACKGROUND/AIM: To describe real clinical outcomes when using systemic therapy to treat non-small cell lung cancer (NSCLC) patients who have anaplastic lymphoma kinase (ALK) fusion gene mutation. PATIENTS AND METHODS: We performed a retrospective chart review from April 2008 to March 2019 sourced from 16 medical institutes that cover a population of three million people. RESULTS: There were 129 ALK rearranged NSCLCpatients. Among them, 103 patients including 40 recurrent disease cases received ALK-tyrosine kinase inhibitors (TKI) and chemotherapy. Our treatment results were comparable to previously reported clinical trials and clinical practice studies. First-line alectinib, treatment sequence of ALK-TKI followed by another ALK-TKI, and pemetrexed-containing chemotherapy contributed to the outcome of treatment. CONCLUSION: By arrangement of treatment such as treatment sequence of ALK-TKI and chemotherapy regimen, it might be possible to obtain a treatment outcome almost equivalent to those of clinical trials even in real clinical practice. Copyright